These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 21826784)

  • 1. Impact of PET-CT on involved field radiotherapy design for pediatric Hodgkin lymphoma.
    Paulino AC; Margolin J; Dreyer Z; Teh BS; Chiang S
    Pediatr Blood Cancer; 2012 Jun; 58(6):860-4. PubMed ID: 21826784
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma.
    Robertson VL; Anderson CS; Keller FG; Halkar R; Goodman M; Marcus RB; Esiashvili N
    Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):324-32. PubMed ID: 20646867
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies.
    Terezakis SA; Hunt MA; Kowalski A; McCann P; Schmidtlein CR; Reiner A; Gönen M; Kirov AS; Gonzales AM; Schöder H; Yahalom J
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):615-22. PubMed ID: 20933343
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma.
    Hutchings M; Loft A; Hansen M; Berthelsen AK; Specht L
    Eur J Haematol; 2007 Mar; 78(3):206-12. PubMed ID: 17253974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
    Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change of initial staging at early remission evaluation with FDG-PET/CT in Hodgkin lymphoma: a report of two cases.
    Molin D; Hagberg H; Suurküla M; Aström G
    Acta Oncol; 2010 May; 49(4):526-8. PubMed ID: 20397779
    [No Abstract]   [Full Text] [Related]  

  • 7. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?
    Girinsky T; Ghalibafian M; Bonniaud G; Bayla A; Magne N; Ferreira I; Lumbroso J
    Radiother Oncol; 2007 Nov; 85(2):178-86. PubMed ID: 17719110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of 18F-fluoro-2-deoxyglucose positron emission tomography on treatment strategy and radiotherapy planning for stage I-II Hodgkin disease: a prospective multicenter study.
    Pommier P; Dussart S; Girinsky T; Chabaud S; Lagrange JL; Nguyen TD; Beckendorff V; D'Hombres A; Artignan X; Bondiau PY; Carrie C; Giammarile F
    Int J Radiat Oncol Biol Phys; 2011 Mar; 79(3):823-8. PubMed ID: 20452732
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Role of FDG-PET in Staging and Therapy of Children with Hodgkin Lymphoma].
    Kluge R; Körholz D
    Klin Padiatr; 2011 Nov; 223(6):315-9. PubMed ID: 22012607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18F]Fluorodeoxyglucose positron emission tomography for detection of bone marrow involvement in children and adolescents with Hodgkin's lymphoma.
    Purz S; Mauz-Körholz C; Körholz D; Hasenclever D; Krausse A; Sorge I; Ruschke K; Stiefel M; Amthauer H; Schober O; Kranert WT; Weber WA; Haberkorn U; Hundsdörfer P; Ehlert K; Becker M; Rössler J; Kulozik AE; Sabri O; Kluge R
    J Clin Oncol; 2011 Sep; 29(26):3523-8. PubMed ID: 21825262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.
    Cerci JJ; Trindade E; Buccheri V; Fanti S; Coutinho AM; Zanoni L; Linardi CC; Celli M; Delbeke D; Pracchia LF; Pitela FA; Soares J; Zinzani PL; Meneghetti JC
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):314-20. PubMed ID: 21816369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
    Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
    Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric nonlymphoblastic non-Hodgkin lymphoma: baseline, interim, and posttreatment PET/CT versus contrast-enhanced CT for evaluation--a prospective study.
    Bakhshi S; Radhakrishnan V; Sharma P; Kumar R; Thulkar S; Vishnubhatla S; Dhawan D; Malhotra A
    Radiology; 2012 Mar; 262(3):956-68. PubMed ID: 22357895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of F-18 FDG PET/CT in assessing bone marrow involvement in pediatric Hodgkin's lymphoma.
    Agrawal K; Mittal BR; Bansal D; Varma N; Srinivasan R; Trehan A; Manohar K; Kashyap R; Bhattacharya A; Marwaha RK
    Ann Nucl Med; 2013 Feb; 27(2):146-51. PubMed ID: 23143537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Routine bone marrow biopsy has little or no therapeutic consequence for positron emission tomography/computed tomography-staged treatment-naive patients with Hodgkin lymphoma.
    El-Galaly TC; d'Amore F; Mylam KJ; de Nully Brown P; Bøgsted M; Bukh A; Specht L; Loft A; Iyer V; Hjorthaug K; Nielsen AL; Christiansen I; Madsen C; Johnsen HE; Hutchings M
    J Clin Oncol; 2012 Dec; 30(36):4508-14. PubMed ID: 23150698
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Are we ready for positron emission tomography/computed tomography-based target volume definition in lymphoma radiation therapy?
    Yeoh KW; Mikhaeel NG
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):14-20. PubMed ID: 22578540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose for initial staging of hodgkin lymphoma: a single center experience in Brazil.
    Cerci JJ; Pracchia LF; Soares Junior J; Linardi Cda C; Meneghetti JC; Buccheri V
    Clinics (Sao Paulo); 2009; 64(6):491-8. PubMed ID: 19578651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can diffusion-weighted whole-body MRI replace contrast-enhanced CT for initial staging of Hodgkin lymphoma in children and adolescents?
    Regacini R; Puchnick A; Luisi FAV; Lederman HM
    Pediatr Radiol; 2018 May; 48(5):638-647. PubMed ID: 29362839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of standardized uptake value thresholding for target volume delineation in pediatric Hodgkin lymphoma.
    Walker AJ; Chirindel A; Hobbs RF; Huynh-Le MP; Moore JA; Cho SY; Terezakis SA
    Pract Radiat Oncol; 2015; 5(4):219-27. PubMed ID: 26146182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed?
    Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF
    Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.